Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic proprietary medicines.
- Market Cap ₹ 53.8 Cr.
- Current Price ₹ 55.7
- High / Low ₹ 85.0 / 54.0
- Stock P/E 36.6
- Book Value ₹ 42.3
- Dividend Yield 1.44 %
- ROCE 5.36 %
- ROE 3.66 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 6.36% over past five years.
- Company has a low return on equity of 4.05% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
28.80 | 34.52 | 38.17 | 38.86 | 42.82 | 49.02 | 49.42 | 48.37 | 58.76 | 65.50 | 65.35 | 67.28 | 67.78 | |
26.86 | 32.43 | 35.74 | 35.97 | 40.97 | 46.55 | 47.33 | 46.92 | 56.60 | 62.62 | 62.86 | 64.98 | 65.34 | |
Operating Profit | 1.94 | 2.09 | 2.43 | 2.89 | 1.85 | 2.47 | 2.09 | 1.45 | 2.16 | 2.88 | 2.49 | 2.30 | 2.44 |
OPM % | 6.74% | 6.05% | 6.37% | 7.44% | 4.32% | 5.04% | 4.23% | 3.00% | 3.68% | 4.40% | 3.81% | 3.42% | 3.60% |
0.29 | 0.33 | 0.14 | 0.12 | 0.56 | 0.12 | 0.57 | 0.45 | 0.19 | 0.08 | 0.33 | 0.42 | 0.41 | |
Interest | 0.63 | 1.06 | 1.37 | 1.64 | 1.49 | 1.23 | 1.01 | 0.43 | 0.11 | 0.11 | 0.08 | 0.06 | 0.08 |
Depreciation | 0.44 | 0.54 | 0.57 | 0.69 | 0.87 | 0.60 | 0.64 | 0.55 | 0.56 | 0.53 | 0.52 | 0.58 | 0.66 |
Profit before tax | 1.16 | 0.82 | 0.63 | 0.68 | 0.05 | 0.76 | 1.01 | 0.92 | 1.68 | 2.32 | 2.22 | 2.08 | 2.11 |
Tax % | 32.76% | 40.24% | 34.92% | 22.06% | 1,000.00% | 26.32% | 34.65% | 21.74% | 35.12% | 31.47% | 31.08% | 29.33% | |
0.78 | 0.50 | 0.41 | 0.54 | -0.44 | 0.56 | 0.67 | 0.72 | 1.09 | 1.59 | 1.52 | 1.46 | 1.47 | |
EPS in Rs | 1.10 | 0.71 | 0.58 | 0.76 | -0.62 | 0.79 | 0.95 | 1.02 | 1.38 | 1.80 | 1.57 | 1.51 | 1.53 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.33% | 41.56% | 0.00% | 52.93% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 6% |
3 Years: | 5% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 17% |
3 Years: | 10% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 31% |
3 Years: | 4% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 4% |
3 Years: | 4% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.08 | 7.92 | 8.81 | 9.66 | 9.66 | 9.66 |
Reserves | 10.63 | 11.13 | 11.06 | 11.60 | 20.33 | 21.00 | 21.71 | 22.16 | 25.57 | 27.66 | 29.58 | 30.93 | 31.19 |
8.33 | 9.99 | 12.47 | 11.39 | 10.56 | 9.42 | 6.17 | 1.25 | 0.02 | 0.00 | 0.00 | 0.00 | 0.52 | |
7.27 | 8.67 | 10.91 | 11.33 | 8.46 | 7.03 | 8.67 | 10.92 | 13.45 | 12.81 | 14.92 | 11.83 | 13.76 | |
Total Liabilities | 33.31 | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.13 |
6.09 | 9.09 | 8.36 | 7.81 | 17.49 | 17.57 | 17.04 | 16.60 | 16.17 | 16.00 | 16.62 | 17.88 | 18.17 | |
CWIP | 2.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.42 | 0.00 | 0.00 |
Investments | 0.67 | 0.69 | 0.70 | 0.73 | 0.99 | 1.12 | 1.13 | 0.82 | 0.24 | 9.11 | 9.66 | 10.43 | 11.69 |
24.03 | 27.09 | 32.46 | 32.86 | 27.95 | 25.84 | 25.46 | 23.99 | 30.55 | 23.69 | 27.46 | 24.11 | 25.27 | |
Total Assets | 33.31 | 36.87 | 41.52 | 41.40 | 46.43 | 44.53 | 43.63 | 41.41 | 46.96 | 49.28 | 54.16 | 52.42 | 55.13 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4.67 | -1.06 | 4.75 | -1.43 | 4.91 | 1.23 | 3.74 | 6.20 | 7.59 | 0.95 | 0.22 | 0.76 | |
-2.10 | -0.70 | -0.18 | 0.05 | -0.59 | -0.62 | -0.10 | -0.37 | -5.58 | -5.47 | 0.53 | -1.31 | |
-0.07 | -0.25 | -1.90 | -2.06 | -2.33 | -1.89 | -4.26 | -5.36 | 1.30 | 0.93 | 0.58 | -0.72 | |
Net Cash Flow | 2.50 | -2.01 | 2.67 | -3.44 | 1.99 | -1.28 | -0.62 | 0.48 | 3.31 | -3.59 | 1.33 | -1.27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 59.57 | 62.38 | 62.73 | 67.16 | 54.13 | 49.81 | 35.45 | 35.32 | 33.23 | 22.23 | 26.75 | 26.42 |
Inventory Days | 207.67 | 233.52 | 210.09 | 206.51 | 152.04 | 146.77 | 191.00 | 208.65 | 117.86 | 115.06 | 167.70 | 137.28 |
Days Payable | 78.35 | 76.75 | 103.39 | 100.86 | 58.22 | 38.75 | 60.93 | 83.69 | 70.57 | 69.63 | 98.30 | 46.96 |
Cash Conversion Cycle | 188.89 | 219.16 | 169.43 | 172.82 | 147.94 | 157.84 | 165.52 | 160.28 | 80.52 | 67.67 | 96.15 | 116.75 |
Working Capital Days | 170.84 | 181.97 | 170.59 | 199.13 | 145.34 | 97.99 | 83.90 | 81.50 | 39.63 | 42.41 | 52.33 | 56.75 |
ROCE % | 7.74% | 6.93% | 6.80% | 7.75% | 4.26% | 5.14% | 5.58% | 4.13% | 5.59% | 6.94% | 6.08% | 5.36% |
Documents
Announcements
- Closure of Trading Window 2d
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
18 Dec - Stop transfer of shares due to loss by holder.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2 Dec
-
Announcement Under Regulation 30 Order To Drop Proceeding
In Respect Of Return After Scrutiny For The Financial Year 2020-2021 Under Section 61 Of CGST Act .
22 Nov - Order received to drop proceedings for FY 2020-2021.
-
Corrigendum To The Unaudited Financial Results Of The Company For The Period Ended On September 30, 2024.
20 Nov - Corrigendum to unaudited financial results for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
Company manufactures over 100 types of products, including oils, syrups, granules, powder, and avlehas, which are marketed under the Sandu brand viz, Sandu Ashoka Compound, Sandu Abhayarishta, Sandu Arvindasav, Sandu Balant Kadha No. 1, Sandu Debix Tablet, Sandu Bhunimbadi Kadha, Sandu Chandanasav Syrup, Sandu Chandraprabha, Sandu Chyavanprash Special, Sandu Dadimavaleha, etc.